Annovis Bio Inc. (NYSE: ANVS) announced the publication of its Phase 2/3 Alzheimer's disease trial results for buntanetap in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE